Post-COVID-19 Outcomes of Patients with Autosomal Dominant Polycystic Kidney Disease: A Multicenter Controlled Study
Authors:
- Serhat KaradagSKSerhat Karadag
- Savas OzturkSOSavas Ozturk
- Nimet AktasNANimet Aktas
- Sinan TrabulusSTSinan Trabulus
- Zeki AydinZAZeki Aydin
- Hamad DheirHDHamad Dheir
- Tolga KuzuTKTolga Kuzu
- Fatih YilmazFYFatih Yilmaz
- Yavuz AyarYAYavuz Ayar
- Irem PembegulIPIrem Pembegul
- Taner BasturkTBTaner Basturk
- Ruya MutluayRMRuya Mutluay
Open Access
- 28 February 2026
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (5) , 1850
Abstract
Background: Patients with chronic kidney disease (CKD), including autosomal dominant polycystic kidney disease (ADPKD), have been reported to be at higher risk for adverse outcomes during the COVID-19 pandemic. We aimed to obtain the characteristics and outcome data obtained in the follow-up of patients with ADPKD who survived COVID-19 and to compare these data with a control group with ADPKD who were COVID-19 naive. Methods: In this national, multicenter observational study, adult ADPKD patients who survived COVID-19 were included, and ADPKD patients without a history of COVID-19 from the same outpatient clinics were selected as a control group. Baseline characteristics and post-COVID-19 first- and third-month data were recorded. Results: In this study, a total of 72 ADPKD patients from 16 centers were included in the study (COVID-19 group, n: 40, non-COVID-19 control group, n: 32). Fourteen (33.3%) patients in the COVID-19 group were hospitalized during active COVID-19. During the first and third months after COVID-19, none of the patients died in either group. Urinary tract infection was significantly higher in the non-COVID-19 group than in the COVID group in the third month (0% vs. 12.5%, p = 0.021). All other follow-up outcomes, including respiratory symptoms and initiation of kidney replacement therapy (KRT), were not different between the groups in the first and third months. The laboratory data of the groups in the first and third months were not significantly different. Hematuria and leukocyturia ratios were also not statistically significantly different between the groups. Conclusions: ADPKD patients who survive COVID-19 have no worse short-term outcomes than non-COVID-19 ADPKD patients, including respiratory symptoms, initiation of KRT, and death.Keywords
This publication has 12 references indexed in Scilit:
- COVID-19 Infection in Autosomal Dominant Polycystic Kidney Disease and Chronic Kidney Disease Patients: Progression of Kidney DiseaseBiomedicines, 2024
- Predictive value of C-reactive protein for disease severity and survival in COVID-19 patients: a systematic review and meta-analysisClinical and Experimental Medicine, 2022
- C-reactive protein and clinical outcomes in patients with COVID-19European Heart Journal, 2021
- The Impact of COVID-19 on Patients With ADPKDCanadian Journal of Kidney Health and Disease, 2021
- Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from TurkeyNephrology Dialysis Transplantation, 2020
- Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-upJournal of Infection, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- Diabetes is a risk factor for the progression and prognosis of COVID‐19Diabetes/Metabolism Research and Reviews, 2020
- Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaborationInternational Journal of Surgery, 2014
- Autosomal Dominant Polycystic Kidney DiseaseNew England Journal of Medicine, 1993